
Nuclidium Secures $99M Series B to Develop Copper-Based Radiopharma Technology
Nuclidium Secures $99M Series B to Advance Copper-Based Radiopharma Platform Swiss biotech Nuclidium has raised approximately $99 million in a Series B funding round to accelerate the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth…







